|
Pathway
|
Rich factor
|
p value
|
Count
|
Symbols
|
| Alzheimer disease |
0.09 |
1.95E-20 |
17 |
APP, CAPN1, CDK5, GRIN1, GRIN2A, GRIN2B, GSK3β, MME, MMP12, PSEN1, PSEN2, PTGS2, ADAM17, NCSTN, BACE1, PSENEN, APH1B |
| Neuroactive ligand-receptor interaction |
0.06 |
7.2E-18 |
17 |
ADORA2A, ADORA2B, AGTR1, TSPO, C5AR1, CHRM2, CHRNA7, CNR2, GABRA5, GRIN1, GRIN2A, GRIN2B, HTR7, MTNR1A, P2RX7, PLG, PTGFR |
| Estrogen signaling pathway |
0.05 |
2.94E-07 |
7 |
AKT1, CTSD, ESR1, ESR2, MMP2, MMP9, RARA |
| Ras signaling pathway |
0.04 |
3.52E-10 |
11 |
ABL1, AKT1, GRIN1, GRIN2A, GRIN2B, HTR7, KDR, KIT, MET, NTRK2, PDGFRB |
| CAMP signaling pathway |
0.05 |
4.37E-10 |
10 |
ADORA2A, AKT1, CFTR, CHRM2, GRIN1, GRIN2A, GRIN2B, PDE4B, PDE4D, PPARA |
| Wnt signaling pathway |
0.03 |
0.000918 |
4 |
CCND1, GSK3β, PPARD, PSEN1 |
| Transcriptional misregulation in cancer |
0.04 |
1.21E-06 |
7 |
MET, MMP3, MMP9, MPO, PLAU, PPARG, RARA |
| Serotonergic synapse |
0.05 |
1.61E-06 |
6 |
ALOX5, APP, HTR7, MAOA, PTGS2, SLC6A4 |
| PPAR signaling pathway |
0.06 |
6.21E-06 |
5 |
TSPO, MMP1, PPARA, PPARD, PPARG |
| IL-17 signaling pathway |
0.05 |
9.11E-06 |
5 |
GSK3β, MMP1, MMP3, MMP9, PTGS2 |
| Arachidonic acid metabolism |
0.06 |
3.69E-05 |
4 |
ALOX5, PTGS2, PTGES, HPGDS |
| Autophagy - animal |
0.04 |
4.27E-05 |
5 |
AKT1, CTSB, CTSD, DAPK1, HIF1A |
| Huntington disease |
0.03 |
5.64E-05 |
6 |
APEX1, GRIN1, GRIN2B, PPARG, PTGS2, SLC6A4 |
| Renin-angiotensin system |
0.11 |
7.24E-05 |
3 |
AGTR1, MME, MMP12 |
| NF-kappa B signaling pathway |
0.04 |
0.000195 |
4 |
PARP1, LCK, PLAU, PTGS2 |
| Th17 cell differentiation |
0.04 |
0.000366 |
4 |
AHR, HIF1A, LCK, RARA |
| Cholinergic synapse |
0.03 |
0.000405 |
4 |
ACHE, AKT1, CHRM2, CHRNA7 |
| Cholesterol metabolism |
0.05 |
0.000714 |
3 |
TSPO, CETP, SOAT1 |
| Complement and coagulation cascades |
0.03 |
0.002458 |
3 |
C5AR1, PLAU, PLG |
| Axon guidance |
0.02 |
0.002906 |
4 |
ABL1, CDK5, GSK3β, MET |
